SuperworthAmgen EPS AMGN
Diluted earnings per share by quarter and over the last twelve months, from 2008.
- Last 12 months, to Jun 30, 2026
- $16.09
- Latest quarter, Q2 FY26
- $4.37
- +65% on a year earlier
- Fiscal year 2025
- $14.23
- +88% on the year before
Amgen's earnings per share was $16.09 over the twelve months to Jun 30, 2026, up 32% on a year earlier.
In its latest quarter, Q2 FY26, it was $4.37, up 65% on the same quarter a year before.
Over the five fiscal years to FY2025 it grew 3% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $14.23 | +88% |
| FY2024 | $7.55 | −40% |
| FY2023 | $12.49 | +3% |
| FY2022 | $12.11 | +17% |
| FY2021 | $10.31 | −16% |
| FY2020 | $12.31 | −4% |
| FY2019 | $12.87 | +2% |
| FY2018 | $12.60 | +390% |
| FY2017 | $2.57 | −75% |
| FY2016 | $10.24 | +13% |
| FY2015 | $9.07 | +35% |
| FY2014 | $6.70 | +1% |
| FY2013 | $6.65 | +21% |
| FY2012 | $5.51 | +37% |
| FY2011 | $4.03 | −16% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $4.37 | +65% | $16.09 | |
| Q1 FY26 | $3.34 | +4% | $14.37 | |
| Q4 FY25 | $2.45 | +111% | $14.23 | |
| Q3 FY25 | $5.93 | +14% | $12.94 | |
| Q2 FY25 | $2.65 | +92% | $12.23 | |
| Q1 FY25 | $3.20 | n/a | $10.96 | |
| Q4 FY24 | $1.16 | −18% | $7.55 | |
| Q3 FY24 | $5.22 | +62% | $7.81 | |
| Q2 FY24 | $1.38 | −46% | $5.81 | |
| Q1 FY24 | −$0.21 | −104% | $7.00 | |
| Q4 FY23 | $1.42 | −53% | $12.49 | |
| Q3 FY23 | $3.22 | −19% | $14.07 |
Against its peers
Companies in Drug Manufacturers - General nearest Amgen's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| AMGNAmgen | $16.09 | +32% a year |
| GILDGilead Sciences | −$2.67 | −153% a year |
| PFEPfizer | $0.76 | −60% a year |
| MRKMerck | $1.25 | −81% a year |
| BMYBristol-Myers Squibb | $4.54 | +83% a year |
| ABBVAbbVie | $3.54 | +69% a year |
| JNJJohnson & Johnson | $6.60 | −36% a year |
| LLYEli Lilly and | $29.80 | +95% a year |
| BIIBBiogen | $5.65 | −46% a year |
| Peer median | $4.04 |
Where Amgen ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Amgen
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.